Abstract
Background: Retrospective studies are conflicting but most of them report that an increase in plasma chromogranin A (CgA) predicts tumor progression in neuroendocrine tumor (NET) patients. Prospectively, we investigated if a change in plasma CgA is associated with tumor burden changes in NET patients with disseminated disease. Methods: We included 239 patients treated at 5 NET centers from December 2010 to December 2013. CgA was measured within 6 weeks of a CT or MRI in a patient undergoing at least 2 scan examinations performed over a period of 1–24 months. In a post hoc analysis, CgA measured 3–6 months prior to the CT/MRI was analyzed. Changes in tumor size were evaluated by RECIST1.1. A 25% change in CgA was chosen to discriminate between increased, decreased, or unchanged levels. Results: In 671 events (2 CT/MRI scans and 2 corresponding CgA measurements), we found a weak positive correlation between the RECIST 1.1 responses and change in plasma CgA from baseline (Spearman’s rank correlation coefficient: 0.15; p < 0.05). Of 304 events in the post hoc analysis, 58 showed progression, 228 showed stable disease, and 18 showed regression, with a median change in CgA of 19% (IQR: 57 to –20%), –12% (23 to –38%), and –73% (–55 to –83%), respectively. The correlation coefficient for all sites was 0.17 (p = 0.003), and it was 0.16 (p = 0.07), 0.18 (p = 0.04), and 0.20 (p = 0.21) for small-intestinal (n = 137), pancreatic (n = 123), and unknown primary NET (n = 40), respectively. In the 58 patients showing tumor progression, the sensitivity and specificity of an increased CgA concentration were 36 and 82%, respectively, with positive and negative predictive values of 32 and 85%. Conclusions: In this prospective study of gastroenteropancreatic NET patients, we observed only a weak association between a change in plasma CgA and changes in tumor burden. CgA as a single biomarker was thus inadequate to predict tumor progression.
References
1.
Helle
KB
. Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system
. Results Probl Cell Differ
. 2010
;50
:21
–44
.
[PubMed]
0080-18442.
Oberg
K
, Jelic
S
. ESMO Guidelines Working Group Neuroendocrine Gastroenteropancreatic tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up
. Ann Oncol
. 2009
;20
:150
–3
.
[PubMed]
0923-75343.
Janson
ET
, Sorbye
H
, Welin
S
, Federspiel
B
, Grønbæk
H
, Hellman
P
, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
. Acta Oncol
. 2014
Oct
;53
(10
):1284
–97
.
[PubMed]
0284-186X4.
Eriksson
B
, Oberg
K
, Stridsberg
M
. Tumor markers in neuroendocrine tumors
. Digestion
. 2000
;62
Suppl 1
:33
–8
.
[PubMed]
0012-28235.
Janson
ET
, Holmberg
L
, Stridsberg
M
, Eriksson
B
, Theodorsson
E
, Wilander
E
, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center
. Ann Oncol
. 1997
Jul
;8
(7
):685
–90
.
[PubMed]
0923-75346.
Zatelli
MC
, Torta
M
, Leon
A
, Ambrosio
MR
, Gion
M
, Tomassetti
P
, et al.; Italian CromaNet Working Group
. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
. Endocr Relat Cancer
. 2007
Jun
;14
(2
):473
–82
.
[PubMed]
1351-00887.
Nobels
FR
, Kwekkeboom
DJ
, Coopmans
W
, Schoenmakers
CH
, Lindemans
J
, De Herder
WW
, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones
. J Clin Endocrinol Metab
. 1997
Aug
;82
(8
):2622
–8
.
[PubMed]
0021-972X8.
Nehar
D
, Lombard-Bohas
C
, Olivieri
S
, Claustrat
B
, Chayvialle
JA
, Penes
MC
, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
. Clin Endocrinol (Oxf)
. 2004
May
;60
(5
):644
–52
.
[PubMed]
0300-06649.
Yao
JC
, Pavel
M
, Phan
AT
, Kulke
MH
, Hoosen
S
, St Peter
J
, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus
. J Clin Endocrinol Metab
. 2011
Dec
;96
(12
):3741
–9
.
[PubMed]
0021-972X10.
Marotta
V
, Nuzzo
V
, Ferrara
T
, Zuccoli
A
, Masone
M
, Nocerino
L
, et al. Limitations of Chromogranin A in clinical practice
. Biomarkers
. 2012
Mar
;17
(2
):186
–91
.
[PubMed]
1354-750X11.
Marotta
V
, Zatelli
MC
, Sciammarella
C
, Ambrosio
MR
, Bondanelli
M
, Colao
A
, Faggiano
A
. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
2018
;25:11-29. 12.
Öberg
K
, Knigge
U
, Kwekkeboom
D
, Perren
A
; ESMO Guidelines Working Group
. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
. Ann Oncol
. 2012
Oct
;23
Suppl 7
:vii124
–30
.
[PubMed]
0923-753413.
Arnold
R
, Chen
YJ
, Costa
F
, Falconi
M
, Gross
D
, Grossman
AB
, et al.; Mallorca Consensus Conference participants
; European Neuroendocrine Tumor Society
. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation
. Neuroendocrinology
. 2009
;90
(2
):227
–33
.
[PubMed]
0028-383514.
Bajetta
E
, Ferrari
L
, Martinetti
A
, Celio
L
, Procopio
G
, Artale
S
, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
. Cancer
. 1999
Sep
;86
(5
):858
–65
.
[PubMed]
0008-543X15.
Matar
S
, Malczewska, Oberg K, Bodei L, Aslanian H, Lewczuk-Myślicka A, Filosso PL, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Kos-Kudła B, Ćwikła JB, Drozdov IA, Kidd M, Modlin IM: Blood Chromogranin A Is not effective as a biomarker for diagnosis or management of bronchopulmonary neuroendocrine tumors/neoplasms. 16.
Jensen
KH
, Hilsted
L
, Jensen
C
, Mynster
T
, Rehfeld
JF
, Knigge
U
. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors
. Scand J Gastroenterol
. 2013
Jan
;48
(1
):70
–7
.
[PubMed]
0036-552117.
Chou
WC
, Chen
JS
, Hung
YS
, Hsu
JT
, Chen
TC
, Sun
CF
, et al. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors
. Anticancer Res
. 2014
Oct
;34
(10
):5661
–9
.
[PubMed]
1791-753018.
Brehm Hoej
L
, Parkner
T
, Soendersoe Knudsen
C
, Grønbaek
H
. A comparison of three chromogranin A assays in patients with neuroendocrine tumours
. J Gastrointestin Liver Dis
. 2014
Dec
;23
(4
):419
–24
.
[PubMed]
1842-112119.
Walter
T
, Chardon
L
, Chopin-laly
X
, Raverot
V
, Caffin
AG
, Chayvialle
JA
, et al. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Eur J Cancer
. 2012
Aug
;48
(12
):1766
–73
.
[PubMed]
0959-804920.
Ćwikła
JB
, Bodei
L
, Kolasinska-Ćwikła
A
, Sankowski
A
, Modlin
IM
, Kidd
M
; CwiklaJB
. Bodei L,Kolasinska-Cwikla A,Sankowski A, Modlin IM,Kidd Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy
. J Clin Endocrinol Metab
. 2015
Nov
;100
(11
):E1437
–45
. 0021-972X21.
Pavel
M
, Jann
H
, Prasad
V
, Drozdov
I
, ModlinIM. KiddM. NET plasma transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology 104 170–182Plasma chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors22.
Tirosh
A
, Papadakis
GZ
, Millo
C
, Sadowski
SM
, Herscovitch
P
, Pacak
K
, Marx
SJ
, Yang
L
, Nockel
P
, Shell
J
, Green
P
, Keutgen
XM
, Patel
D
, Nilubol
N
, Kebebew
E
. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements.23.
Tirosh
A
, Kebebew
E
. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors
. Future Oncol
. 2018
Jan
;14
(2
):111
–22
.
[PubMed]
1479-669424.
Buil-Bruna
N
, Dehez
M
, Manon
A
, Nguyen
TX
, Trocóniz
IF
. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
. AAPS J
. 2016
May
;18
(3
):703
–12
.
[PubMed]
1550-741625.
Oberg
K
, Krenning
E
, Sundin
A
, Bodei
L
, Kidd
M
, Tesselaar
M
, et al. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
. Endocr Connect
. 2016
Sep
;5
(5
):174
–87
.
[PubMed]
2049-361426.
Singh
S
, Moody
L
, Chan
DL
, Metz
DC
, Strosberg
J
, Asmis
T
, et al.; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group
. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors
. JAMA Oncol
. 2018
Nov
;4
(11
):1597
–604
.
[PubMed]
2374-2437© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
